Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 10/20 | 0.43 |
| ▸ | MMP1 | P03956 | 6/20 | 0.43 |
| ▸ | MMP3 | P08254 | 5/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.43 |
| ▸ | ADAM9 | Q13443 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | AREG | P15514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920302 | 0.86 | HDAC8 (0.53) | HDAC8MMP9MMP1MMP3ADAM17 | |
| SCHEMBL6920539 | 0.85 | HTR1A (0.50) | HDAC8MMP9MMP1MMP3ADAM17 | |
| SCHEMBL11562455 | 0.84 | MMP9 (0.45) | HDAC8FABP7FABP5MMP9MMP1 | |
| SCHEMBL21869793 | 0.77 | POLB (0.58) | — | |
| SCHEMBL7449941 | 0.76 | KDM4E (0.56) | — | |
| SCHEMBL15654181 | 0.75 | NR1D1 (0.50) | NR1D1 | |
| SCHEMBL22926792 | 0.75 | MAOB (0.51) | FABP7FABP5 | |
| SCHEMBL5351382 | 0.74 | NPSR1 (0.48) | NR1D1MMP9MMP1MMP3ADAM17 | |
| SCHEMBL16589449 | 0.74 | FKBP1A (0.49) | FABP7FABP5 | |
| SCHEMBL11563644 | 0.74 | FKBP1A (0.42) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004041816-A1 | AZACYCLIC COMPOUNDS AS OREXIN RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2004-05-21 | — | — | WO | disclosed |